Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

Diabetes Drug Might Help Detect and Treat Alzheimer’s Disease

By BOSTON UNIVERSITY MEDICAL CENTER | March 9, 2017

Diabetes drug shows promise for safely treating, detecting Alzheimer’s disease.

As the number of patients with Alzheimer’s disease (AD) rapidly increases, new treatments as well as blood tests that are simple and can be easily performed in a doctor’s office to diagnose are urgently needed.

A new study has found treatment with the diabetes drug amylin (or pramlintide) safely improves learning and memory function in AD patients and reduces the AD pathology in their brains. The findings, which appear in the Journal Translational Research and Clinical Interventions, also may lead to the development of a blood test for AD. 

Currently, lumbar punctures to detect biomarkers in cerebrospinal fluid and positron emission tomography imaging scans are used to diagnose AD. Unfortunately many patients are fearful of these procedures and the high cost is prohibitive. 

“A single injection of pramlintide into our patients was well tolerated and reduced the amyloid burden as well as lowered the concentrations of amyloid-β peptides, a major component of AD in the brain,” explained corresponding author Wendy Qiu, MD, PhD, associate professor of psychiatry and pharmacology and experimental therapeutics at Boston University School of Medicine. 

“Our study suggests a potential role for the creation of a blood test that relies on pramlintide, which could cross the blood-brain barrier and help to translocate the biomarkers related to AD pathology including amyloid-β peptides and neuroinflammation, from the brain into the bloodstream where they can be detected,” added Qiu. 

Funding for this study was provided by grants from the Alzheimer’s Disease Association (IIRG-13-284238), NIA (R21 AG045757A1), and Ignition Award (to W.Q.Q), and from Boston University Alzheimer’s Disease Center pilot grant (to H.Z.).

(Source: EurekAlert!)


Filed Under: Drug Discovery

 

Related Articles Read More >

Zoliflodacin wins FDA nod for treatment of gonorrhea
FDA approved ENFLONSIA for the prevention of RSV in Infants
First clinical study results of Dupixent for atopic dermatitis in patients with darker skin tones 
Labcorp widens precision oncology toolkit, aims to speed drug-trial enrollment
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE